JP7444786B2 - 低用量の安定なグルカゴンを使用する肥満治療手術後の低血糖症の処置 - Google Patents

低用量の安定なグルカゴンを使用する肥満治療手術後の低血糖症の処置 Download PDF

Info

Publication number
JP7444786B2
JP7444786B2 JP2020561591A JP2020561591A JP7444786B2 JP 7444786 B2 JP7444786 B2 JP 7444786B2 JP 2020561591 A JP2020561591 A JP 2020561591A JP 2020561591 A JP2020561591 A JP 2020561591A JP 7444786 B2 JP7444786 B2 JP 7444786B2
Authority
JP
Japan
Prior art keywords
minutes
glucagon
therapeutic agent
less
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020561591A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511386A (ja
JP2021511386A5 (https=
JPWO2019147718A5 (https=
Inventor
ブレット ニュースワンガー
スティーブン ジェイ． プレストレルスキ
メアリー－エリザベス パティ
Original Assignee
ゼリス ファーマシューティカルズ インコーポレイテッド
ジョスリン ダイアビーティス センター インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゼリス ファーマシューティカルズ インコーポレイテッド, ジョスリン ダイアビーティス センター インコーポレイテッド filed Critical ゼリス ファーマシューティカルズ インコーポレイテッド
Publication of JP2021511386A publication Critical patent/JP2021511386A/ja
Publication of JP2021511386A5 publication Critical patent/JP2021511386A5/ja
Publication of JPWO2019147718A5 publication Critical patent/JPWO2019147718A5/ja
Application granted granted Critical
Publication of JP7444786B2 publication Critical patent/JP7444786B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2020561591A 2018-01-23 2019-01-23 低用量の安定なグルカゴンを使用する肥満治療手術後の低血糖症の処置 Active JP7444786B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862620861P 2018-01-23 2018-01-23
US62/620,861 2018-01-23
PCT/US2019/014815 WO2019147718A1 (en) 2018-01-23 2019-01-23 Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon

Publications (4)

Publication Number Publication Date
JP2021511386A JP2021511386A (ja) 2021-05-06
JP2021511386A5 JP2021511386A5 (https=) 2022-01-31
JPWO2019147718A5 JPWO2019147718A5 (https=) 2022-01-31
JP7444786B2 true JP7444786B2 (ja) 2024-03-06

Family

ID=65352189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561591A Active JP7444786B2 (ja) 2018-01-23 2019-01-23 低用量の安定なグルカゴンを使用する肥満治療手術後の低血糖症の処置

Country Status (9)

Country Link
US (1) US20210030847A1 (https=)
EP (1) EP3743097A1 (https=)
JP (1) JP7444786B2 (https=)
KR (1) KR20200134213A (https=)
CN (1) CN111936159A (https=)
AU (1) AU2019211352A1 (https=)
BR (1) BR112020014719A2 (https=)
MX (1) MX2020007768A (https=)
WO (1) WO2019147718A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026899A1 (en) * 2016-08-03 2018-02-08 Joslin Diabetes Center, Inc. Methods and compositions for treating hypoglycemia
US12543982B2 (en) 2021-01-22 2026-02-10 Cilag Gmbh International Method of adjusting a surgical parameter based on biomarker measurements
US12569203B2 (en) * 2021-01-22 2026-03-10 Cilag Gmbh International Bariatric surgery post-surgical monitoring
US12527515B2 (en) 2021-01-22 2026-01-20 Cilag Gmbh International Colorectal surgery post-surgical monitoring
US12128089B2 (en) * 2022-05-26 2024-10-29 Slayback Pharma Llc Stable liquid compositions of glucagon

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523620A (ja) 2010-03-26 2013-06-17 ノヴォ ノルディスク アー／エス 新規のグルカゴンアナログ
JP2014507484A (ja) 2011-03-10 2014-03-27 ゼリス ファーマシューティカルズ インコーポレイテッド ペプチド薬物の非経口注射用の安定な製剤
JP2014510739A (ja) 2011-03-28 2014-05-01 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
JP2015524419A (ja) 2012-07-23 2015-08-24 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
WO2016196976A1 (en) 2015-06-04 2016-12-08 Xeris Pharmaceuticals, Inc. Glucagon delivery apparatuses and related methods
JP2017505331A (ja) 2014-02-06 2017-02-16 ゼリス ファーマシューティカルズ インコーポレイテッド 安定なペプチド製剤、および調製のための方法
WO2017053922A1 (en) 2015-09-25 2017-03-30 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY185334A (en) * 2014-12-30 2021-05-06 Hanmi Pharm Ind Co Ltd Glucagon derivatives with improved stability
AU2016267052B2 (en) * 2015-05-22 2022-01-20 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with GLP-1 antagonists
AU2016304588A1 (en) * 2015-08-06 2018-02-15 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
GB201710822D0 (en) * 2017-07-05 2017-08-16 Zealand Pharma As Methods and medical uses relating to the treatment of hypoglycaemia

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523620A (ja) 2010-03-26 2013-06-17 ノヴォ ノルディスク アー／エス 新規のグルカゴンアナログ
JP2014507484A (ja) 2011-03-10 2014-03-27 ゼリス ファーマシューティカルズ インコーポレイテッド ペプチド薬物の非経口注射用の安定な製剤
JP2014510739A (ja) 2011-03-28 2014-05-01 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
JP2015524419A (ja) 2012-07-23 2015-08-24 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
JP2017505331A (ja) 2014-02-06 2017-02-16 ゼリス ファーマシューティカルズ インコーポレイテッド 安定なペプチド製剤、および調製のための方法
WO2016196976A1 (en) 2015-06-04 2016-12-08 Xeris Pharmaceuticals, Inc. Glucagon delivery apparatuses and related methods
WO2017053922A1 (en) 2015-09-25 2017-03-30 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
JP2018528242A (ja) 2015-09-25 2018-09-27 ゼリス ファーマシューティカルズ インコーポレイテッド 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法

Also Published As

Publication number Publication date
JP2021511386A (ja) 2021-05-06
BR112020014719A2 (pt) 2020-12-08
MX2020007768A (es) 2020-11-12
WO2019147718A8 (en) 2020-08-06
AU2019211352A1 (en) 2020-07-30
EP3743097A1 (en) 2020-12-02
KR20200134213A (ko) 2020-12-01
WO2019147718A1 (en) 2019-08-01
US20210030847A1 (en) 2021-02-04
CN111936159A (zh) 2020-11-13

Similar Documents

Publication Publication Date Title
US20240207365A1 (en) Methods for producing stable therapeutic formulations in aprotic polar solvents
JP7444786B2 (ja) 低用量の安定なグルカゴンを使用する肥満治療手術後の低血糖症の処置
US12514907B2 (en) Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes
US20240238381A1 (en) Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
US11590205B2 (en) Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
HK40101667B (en) Methods for producing stable therapeutic formulations in aprotic polar solvents
HK40101667A (en) Methods for producing stable therapeutic formulations in aprotic polar solvents
HK1250644B (en) Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201102

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230913

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240222

R150 Certificate of patent or registration of utility model

Ref document number: 7444786

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150